Follow the BELITE BIO, INC stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €6.8bn. The latest transaction was reported on 14 August 2026 (Cession). Among the most active insiders: MATA NATHAN L.. Every trade is free.
107
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€4m
105 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BELITE BIO, INC Strong Buy (bullish), based on 8 analysts. Average price target: US$214.00.
40Σ signal
Buys n/a€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
340 shares@ US$157.37170.0008% mcap6.7% of flowAmerican depositary shareSEC:0001193125-26-201466:2
25 of 107 declarations
About BELITE BIO, INC
BELITE BIO, INC is a company listed on XNAS, focused on developing treatments for metabolic diseases and eye disorders. It emphasizes innovation in the biotechnology sector.